Premium
Long‐term treatment results of Polish pediatric and adolescent patients enrolled in the ALL IC‐BFM 2002 trial
Author(s) -
Kowalczyk Jerzy R.,
Zawitkowska Joanna,
Lejman Monika,
Drabko Katarzyna,
Samardakiewicz Marzena,
Matysiak Michał,
Romiszewski Michał,
Balwierz Walentyna,
Ćwiklińska Magdalena,
Kazanowska Bernarda,
OwocLempach Joanna,
Wachowiak Jacek,
Derwich Katarzyna,
AdamkiewiczDrożyńska Elżbieta,
Niedźwiecki Maciej,
Trelińska Joanna,
Młynarski Wojciech,
Wysocki Mariusz,
Kołtan Andrzej,
Szczepański Tomasz,
KrawczukRybak Maryna,
Kitszel Anna,
Wieczorek Maria,
Urasiński Tomasz,
Ociepa Tomasz,
SobolMilejska Grażyna,
MiziaMalarz Agnieszka,
Karolczyk Grażyna,
Stary Jan
Publication year - 2019
Publication title -
american journal of hematology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 2.456
H-Index - 105
eISSN - 1096-8652
pISSN - 0361-8609
DOI - 10.1002/ajh.25619
Subject(s) - medicine , term (time) , pediatrics , physics , quantum mechanics
The aim of study was analysis of the treatment results of the ALL IC-BFM 2002 trial in patients with acute lymphoblastic leukemia (ALL) treated in Polish pediatric oncohematology centres. Between November 2002 and November 2011, 1872 children aged 1-17 with newly diagnosed ALL were consecutively enrolled in the ALL IC BFM 2002 protocol. The follow-up was updated as of December 31, 2016. The study group included 56.6% males and 43.4% females. According to risk stratification, 32.6% of the children were qualified for a standard risk group (SR), 48.1% - intermediate risk (IR), 19.3% - high risk (HR). A total of 268 (14.3%) deaths were noted in the entire group. Cumulative death risk in SR group after 5 years was estimated at 4.4%, 14.2% in IR group, and 37.3% in HR. The incidence of death at complete remission (CR) was significantly higher in children aged ≥10 versus younger children (9.3% v 2.6%; P<0.001), in T-ALL versus BCP-ALL (9% v 3.5%; P<0.001), but differences were not found between girls and boys (4.0% v 4.5%; P=0.7). Relapses occurred in 275 children (14.7%), of which 51 cases occurred in SR group (8.4% of the patients who were stratified for the SR group), 147 in IR (16.4%), 77 in HR (21.2%). Overall survival for 1872 children with ALL was 86% after 5 years, whereas the EFS rate was 79%. ALL IC-BFM 2002 proved as a highly effective protocol for treatment of children with ALL in Polish pediatric oncohematology centres. This article is protected by copyright. All rights reserved.